
Piramal Pharma Q1 Results FY26: Q1 Loss Narrows 7.83% to ₹81.70 Crore; Revenue Fails 0.89% YoY
Posted by : sachet | Tue Jul 29 2025

Piramal Pharma Q1 Results FY26: Piramal Pharma posted its Q1 results on 28th July 2025. The company posted robust numbers, with Q1 PAT standing at ₹-81.70 crores against revenue of ₹1,933.71 crores. During Q1 FY26, the company’s loss narrowed to 7.83% YoY, and its revenue decreased by 0.89% for the same period.
Piramal Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)
Particulars | Quarter Ended | |
30-06-2025 | 30-06-2024 | |
Revenue from Operations | ₹1,933.71 | ₹1,951.14 |
Profit Before Tax (PBT) | ₹165.10 | ₹224.03 |
Profit After Tax (PAT) | ₹-81.70 | ₹-88.64 |
(Figures in crores)
Piramal Pharma Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)
Particulars | Quarter Ended | |
30-06-2025 | 30-06-2024 | |
Revenue from Operations | ₹969.88 | ₹1,063.20 |
Profit Before Tax (PBT) | ₹225.25 | ₹188.39 |
Profit After Tax (PAT) | ₹113.14 | ₹85.27 |
(Figures in crores)
Piramal Pharma Q1 Results FY26 Highlights (Q1 FY26 vs FY25)
- Piramal Pharma clocked Q1 FY26 consolidated revenue of ₹1,933.71 crores vs ₹1,951.14 crores.
- On the profit front, Piramal Pharma’s loss narrowed to ₹81.70 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹-88.64 crore.
- Consolidated PAT rose for the first quarter of FY26, was 7.83% YoY, and revenue fell 0.89% YoY.
- As per the standalone figures, the quarterly PAT of Piramal Pharma has increased by 32.68% and revenue has decreased by 8.78% YoY.
Piramal Pharma Share Price Performance
On the opening bell of 29th July 2025, the shares of Piramal Pharma opened at ₹197.34 per share. However, the initial gains are wiped out as of now, and Piramal Pharma shares are trading at ₹203.51 per share, higher than their opening price.
Considering the long-term performance, Piramal Pharma shares have yielded close to 20.51% returns in the past 1 year, and 5-year returns stand at 3.66%. Over the maximum timeframe, the Piramal Pharma share provided 4.63% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Piramal Pharma shares after thorough research.
For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Recent Articles
Laxmi India Finance IPO GMP: Day 1 IPO Live Updates
Waaree Energies Q1 Results FY26: Q1 PAT Rose 89.07% to ₹745.20 Crore; Revenue Surged 29.83% YoY
Aditiya Infotech IPO GMP: Day 1 IPO Live Updates
Adani Green Q1 Results FY26: Q1 PAT Rose 59.87% to ₹713.00 Crore; Revenue Surged 36.01% YoY
Premier Energies Q1 Results FY26: Q1 PAT Rose 55.33% to ₹307.79 Crore; Revenue Surged 9.86% YoY
Ajanta Pharma Q1 Results FY26: Q1 PAT Rose 3.89% to ₹255.34 Crore; Revenue Surged 13.78% YoY
Related Posts
NIS Management IPO GMP & Review: Apply or Avoid?
Commodity Market | Everything You Should Know in 2025
Stock Market Today: Sensex Drops 695.82 Points Down; Nifty Scales 24,886.50 | Check More Updates
Shradha Infra Q1 Results FY26: Q1 PAT Fall 24.76% to ₹3.78 Crore; Revenue Down 9.85% YoY
AB Infrabuild Q1 Results FY26: Q1 PAT Rises 844.65% to ₹5.12 Crore; Revenue Up 328.01% YoY
